Literature DB >> 17157294

Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model.

Eugene F du Toit1, Sonia Genade, Sophia Carlini, Johan A Moolman, Friedrich Brunner, Amanda Lochner.   

Abstract

We recently demonstrated that exogenous nitric oxide (NO) acts as a trigger for preconditioning in the isolated rat heart model. There is however little data concerning the effects of elevated cardiac endothelial nitric oxide synthase (eNOS) expression on myocardial tolerance to ischaemia. Similarly, the effects of gender and eNOS overexpression on ischaemic preconditioning is unknown. We hypothesized that: 1) eNOS overexpression increases myocardial tolerance to ischaemia, and, 2) eNOS overexpressed hearts cannot be preconditioned, since the hearts are already maximally protected. Male and female wild-type and transgenic mice that overexpress eNOS exclusively in cardiac myocytes were perfused in the working heart mode with a modified Krebs-Henseleit buffer at a pre-load of 12.5 mm Hg and afterload of 50 mm Hg. Cardiac output, coronary flow, peak aortic systolic pressure and total work were determined before hearts were preconditioned by 4x5 min cycles of ischaemia/reperfusion, and then subjected to 20 min total global ischaemia, followed by reperfusion. Reperfusion function and myocardial infarct size were used as endpoints. Pre-ischaemic mechanical function (rate pressure product and cardiac output) was similar for wild-type and transgenic mice of both sexes. The eNOS overexpressed hearts had smaller infarcts than the hearts from their wild-type littermates (26.9+/-1.4% vs. 37.0+/-2.1% for controls, P<0.05). Preconditioning the eNOS overexpressed hearts resulted in infarct sizes comparable with control non-preconditioned hearts (27.5+/-2.0% vs. 26.9+/-1.4% for controls). Myocardial cGMP levels were elevated during sustained ischaemia in the transgenic hearts when compared with wild-type hearts (22.43+/-1.63 pmol/g ww vs 16.54+/-1.48 pmol/g ww, P<0.05). Preconditioning also elevated myocardial cGMP levels during sustained ischaemia in the wild-type hearts (26.77+/-2.81 pmol/g ww, P<0.05). We conclude that: 1) basal mechanical function is similar for both wild-type and transgenic mice of both sexes, 2) reperfusion function and infarct size was also similar for both sexes under both control conditions and after preconditioning, 3) the transgenic mice are more tolerant of ischaemia as reflected by their smaller myocardial infarcts, and, 4) the eNOS overexpressed mouse heart cannot be preconditioned regardless of whether mechanical function or infarct size is used as an end-point. These hearts may be maximally protected against ischaemia/reperfusion injury by their elevated endogenous NO levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157294     DOI: 10.1016/j.ejphar.2006.11.004

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Stabilizing endothelium of donor hearts with fusogenic liposomes reduces myocardial injury and dysfunction.

Authors:  Tathyana F Fensterer; W Brent Keeling; Phani K Patibandla; Sathnur Pushpakumar; Gustavo Perez-Abadia; Philip Bauer; Chirag V Soni; Gary L Anderson; Claudio Maldonado
Journal:  J Surg Res       Date:  2012-10-30       Impact factor: 2.192

2.  Age- and gender-related changes in ventricular performance in wild-type FVB/N mice as evaluated by conventional and vector velocity echocardiography imaging: a retrospective study.

Authors:  Sheryl E Koch; Kevin J Haworth; Nathan Robbins; Margaret A Smith; Navneet Lather; Ahmad Anjak; Min Jiang; Priyanka Varma; W Keith Jones; Jack Rubinstein
Journal:  Ultrasound Med Biol       Date:  2013-06-19       Impact factor: 2.998

Review 3.  Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors:  D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

4.  Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis.

Authors:  James J DiNicolantonio; Tian Hu; Carl J Lavie; James H O'Keefe; Sripal Bangalore
Journal:  Ochsner J       Date:  2014

5.  miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1.

Authors:  Alicia M Evangelista; Anne M Deschamps; Delong Liu; Nalini Raghavachari; Elizabeth Murphy
Journal:  Physiol Genomics       Date:  2013-04-30       Impact factor: 3.107

6.  eNOS is required for acute in vivo ischemic preconditioning of the heart: effects of ischemic duration and sex.

Authors:  M A Hassan Talukder; Fuchun Yang; Hiroaki Shimokawa; Jay L Zweier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-04       Impact factor: 4.733

Review 7.  Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury.

Authors:  Punate Weerateerangkul; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Med Sci Monit       Date:  2011-02

Review 8.  Altered Nitric Oxide System in Cardiovascular and Renal Diseases.

Authors:  JongUn Lee; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  Chonnam Med J       Date:  2016-05-20

9.  Cardioprotective Action of Ginkgo biloba Extract against Sustained β-Adrenergic Stimulation Occurs via Activation of M2/NO Pathway.

Authors:  Thássio R R Mesquita; Itamar C G de Jesus; Jucilene F Dos Santos; Grace K M de Almeida; Carla M L de Vasconcelos; Silvia Guatimosim; Fabrício N Macedo; Robervan V Dos Santos; José E R de Menezes-Filho; Rodrigo Miguel-Dos-Santos; Paulo T D Matos; Sérgio Scalzo; Valter J Santana-Filho; Ricardo L C Albuquerque-Júnior; Rose N Pereira-Filho; Sandra Lauton-Santos
Journal:  Front Pharmacol       Date:  2017-05-11       Impact factor: 5.810

10.  Lysophosphatidylcholine up-regulates human endothelial nitric oxide synthase gene transactivity by c-Jun N-terminal kinase signalling pathway.

Authors:  Feiyue Xing; Jing Liu; Yongyan Mo; Zhifeng Liu; Qinghe Qin; Jingzhen Wang; Zhenhua Fan; Yutian Long; Na Liu; Kesen Zhao; Yong Jiang
Journal:  J Cell Mol Med       Date:  2008-06-20       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.